1262859-53-9

Upstream product

• 460-00-4 1-Bromo-4-fluorobenzene 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 1206774-43-7 1-(5-bromo-2-fluorophenyl)-1-methylethanol 
• 123-31-9 hydroquinone 

Downstream Products

• 1262859-55-1 (S)-2-(5-bromo-2-fluoro-phenyl)-propane-1,2-diol 
• 1346146-67-5 (RS)-4-bromo-1-fluoro-2-(2-iodo-1-isocyanato-1-methyl-ethyl)-benzene 
• 1266785-96-9 (R)-2-(5-bromo-2-fluoro-phenyl)-2-(4-methoxy-benzylamino)-propan-1-ol 
• 1228571-14-9 (2R)-2-amino-2-(5-bromo-2-fluorophenyl)propan-1-ol 
• 1346146-72-2 (R)-4-(5-bromo-2-fluorophenyl)-4-methyloxazolidin-2-one 
• 1392104-97-0 (S)-(+)-4-(5-bromo-2-fluoro-phenyl)-4-methyl-oxazolidin-2-one 
• 1346146-75-5 (R)-3-(5-bromo-2-fluoro-phenyl)-3-methyl-[1,4]oxazepan-5-one 
• 1346146-77-7 (R)-3-[5-(benzhydrylidene-amino)-2-fluoro-phenyl]-3-methyl-[1,4]oxazepan-5-one 
• 1346146-78-8 (R)-3-(5-amino-2-fluoro-phenyl)-3-methyl-[1,4]oxazepan-5-one hydrochloride 
• 1346146-79-9 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [4-fluoro-3-((R)-3-methyl-5-oxo-[1,4]oxazepan-3-yl)phenyl]amide 
• 1346146-82-4 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((R)-5-ethoxy-3-methyl-2,3,6,7-tetrahydro-[1,4]oxazepin-3-yl)-4-fluorophenyl]amide 
• 1262859-57-3 (S)-2-(5-bromo-2-fluoro-phenyl)-2-methyl-oxirane 
• 1262855-97-9 5-cyano-3-methyl-pyridine-2-carboxylic acid [3-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-4-fluoro-phenyl]-amide hydrochloride 
• 1262855-96-8 N-(3-((3R,6R)-5-amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-bromopyrimidine-2-carboxamide hydrochloride 

Relevant academic research and scientific papers

OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprising them.

Oxazine Derivatives and their Use in the Treatment of Neurological Disorders

The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

Oxazine derivatives and their use in the treatment of neurological disorders

The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present

OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS

This invention relates to compounds of the formula (I), wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as 5 medicam

2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS

This invention relates to compounds of the formula wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments fo